StockWatch
·

Sanofi Consumer Healthcare India Ltd

BSE: 544250

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
267.50
+10.5%+12.9%
Expenditure
164.80
+9.8%+7.9%
Net Profit
76.60
+11.3%+21.8%
OPM %
38.65%
+0.76pp+2.31pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00206.50413.00619.50826.00Q3 FY25Q4 FY25Q1 FY26Q1 FY25Q2 FY26Q2 FY25Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Sanofi Consumer Healthcare: Q2 FY27 PAT +22% YoY, margins expand on domestic growth

consumer healthcare · pharma · margin expansion

ResultsQ2 FY2728 Oct 20263 minPharma & Healthcare

Can Sanofi Consumer Healthcare Sustain Growth Momentum Into H2?

consumer healthcare · pharma · Q2 FY27

Result previewQ2 FY2726 Oct 20263 minPharma & Healthcare

Sanofi Consumer Healthcare: PAT ₹68.8 Cr, +27% adjusted YoY as relaunches lift margins

consumer healthcare · pharmaceuticals · margin expansion

ResultsQ1 FY2728 Jul 20263 minPharma & Healthcare
Latest
Board Meeting28 Oct, 6:30 pm

Sanofi Consumer Healthcare: Q2 FY27 PAT +22% YoY, margins expand on domestic growth

Sanofi Consumer Healthcare India's standalone revenue for the quarter ended September 30, 2026 (Q2 FY27 on our Apr-Mar convention; the company labels it 'Q3'26' under its Jan-Dec fiscal year) came in at ₹263.1 Cr, up 12.5% YoY and 11.6% QoQ, with PAT of ₹76.6 Cr, up 21.8% YoY and 11.3% QoQ. Both lines beat the bar set in our pre-result preview, which had flagged ~7% YoY revenue growth and PBT of ₹90-95 Cr as the expected range for a stock that trades 45% below its 52-week high on thin analyst coverage; actual PBT of ₹102.7 Cr (+22% YoY) cleared that range. No one-off items sit in either this quarter or the year-ago comparator quarter, so the headline growth is also the clean underlying growth — no adjusted-vs-reported split applies here. Margin expansion did real work alongside topline growth: operating margin (EBITDA/revenue) rose to roughly 38.7% from 36.3% a year ago and 37.9% last quarter, while net margin improved to 29.1% from 26.9% YoY. The expense base held largely in line with revenue — cost of materials consumed was flat YoY at ₹40.7 Cr while other expenses rose about 20% YoY to ₹66.3 Cr — leaving operating leverage from the 19% YoY domestic sales growth management cited as the main driver, alongside the volume expansion and market-share gains it claims across key brands (Allegra, DePURA, Avil, Combiflam). Management gives no formal forward guidance on record, so this quarter cannot be graded against a prior company outlook — only against the street/preview expectations, which it beat. MD Himanshu Bakshi framed the quarter as reflecting "disciplined execution" and investment in brand building and distribution/HCP reach, consistent with the domestic-led growth in the numbers. The nine-month FY27 picture (revenue ₹728 Cr, +16% YoY; PBT +24% YoY) looks stronger than the single quarter, but the company itself flags that the nine-month comparison isn't fully clean — the FY25 base includes a phased product-recall relaunch (Combiflam Suspension back in Q2 2025, Allegra Suspension and Depura Kids in Q3 2025) that depressed prior-year quarters unevenly. The only corporate development in the window is the October 28 board meeting that approved these results; the Q3 FY27 trading-window closure noted in our event records is routine and doesn't bear on this print.

28 Oct 2026, 06:30 pm

Corporate Events

Board MeetingSANOFICONR
2026
28Oct

Board Meeting

The meeting of the Board of Directors of the Company will be…

BSE Filing ↗
Board MeetingSANOFICONR
2026
28Jul

Board Meeting

The meeting of the Board of Directors of the Company will be…

BSE Filing ↗
Board MeetingSANOFICONR
2026
26Jun

Board Meeting

The 3rd Annual General Meeting (AGM) of the Company will be …

BSE Filing ↗
DividendSANOFICONR
2026
19Jun

₹75 / share

BSE Filing ↗
Board MeetingSANOFICONR
2026
25Feb

Board Meeting

To consider and approve the Audited Financial Statements for…

BSE Filing ↗
DividendSANOFICONR
2025
28Apr

₹55 / share

BSE Filing ↗
DividendSANOFICONR
2025
17Apr

₹55 / share

BSE Filing ↗
Board MeetingSANOFICONR
2024
12Nov

Board Meeting

Consideration And Approval Of The Unaudited Financial Statem…

BSE Filing ↗